The recent success of Wegovy, a drug developed by Novo Nordisk, in reducing cardiovascular events among obese adults is being hailed as a significant win for both the company and its competitor, Eli Lilly & Co. This achievement holds positive implications for the obesity category as a whole, according to analysts at Wolfe Research.
The primary goal of the study was to demonstrate that weight loss achieved through the use of Wegovy could lead to a decrease in major adverse cardiovascular events (MACE), such as heart attacks. Remarkably, this key endpoint was successfully met. In their note to clients, the analysts headed by Dr. Tim Anderson commented, “Results are VERY strong.” The anticipated 20% reduction in cardio events surpassed expectations, benefiting patients in terms of cardiovascular death, myocardial infarction, and stroke.
Wolfe Research initially estimated the odds of success at 50/50, but the consensus had more favorable odds. Novo Nordisk had exuded confidence in the trial’s outcome. Thus, this outcome has positioned both Novo Nordisk and Eli Lilly & Co. for success.
The significance of this trial extends beyond the individual companies involved. Treating obesity with prescription drugs is a controversial matter that has faced resistance from payers, both in the US and internationally. Historically, such drugs were deemed a “lifestyle” issue and therefore not covered by many insurance plans. This places the burden on patients to pay out-of-pocket for their medications, similar to other lifestyle categories like smoking cessation and erectile dysfunction.
In conclusion, the success of Wegovy in reducing cardiovascular events marks a major breakthrough for the obesity category. It not only benefits Novo Nordisk but also Eli Lilly & Co., demonstrating the effectiveness of prescription drugs in treating obesity and potentially changing payer views on coverage.
